Wednesday, May 13, 2026 The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This analysis focused on long-term survival and exploratory plasma sequencing analysis identified concurrent mutations in DNA damage repair genes. Renouf DJ, Topham JT, Loree JM, Schaeffer DF, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko Y-J, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Karasinska JM, Gill S, Tu D, O’Callaghan CJ. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. Nature Communications 17: 3631. 2026.https://doi.org/10.1038/s41467-026-70120-z
